Researchers found that functional assays could improve the classification of cystic fibrosis-related missense variants with variable disease expressivity.
Owlstone will give AstraZeneca access to its Breath Biopsy Services to identify breath-based biomarkers for stratifying and treating asthma and COPD patients.
While point-of-care molecular testing of patients with respiratory illness wasn't associated with lower antibiotic use, patients tested had shorter drug courses.
